JP2025514278A - 上部顔面の皺線の処置 - Google Patents

上部顔面の皺線の処置 Download PDF

Info

Publication number
JP2025514278A
JP2025514278A JP2024563506A JP2024563506A JP2025514278A JP 2025514278 A JP2025514278 A JP 2025514278A JP 2024563506 A JP2024563506 A JP 2024563506A JP 2024563506 A JP2024563506 A JP 2024563506A JP 2025514278 A JP2025514278 A JP 2025514278A
Authority
JP
Japan
Prior art keywords
modified bont
bont
lines
administered
modified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024563506A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025514278A5 (enExample
Inventor
グリゴール，ニコラエ
ポンス，ローラン
ラッフル，ケイティー
ピコー，フィリップ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ipsen Biopharm Ltd
Original Assignee
Ipsen Biopharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ipsen Biopharm Ltd filed Critical Ipsen Biopharm Ltd
Publication of JP2025514278A publication Critical patent/JP2025514278A/ja
Publication of JP2025514278A5 publication Critical patent/JP2025514278A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/66—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/91—Injection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
JP2024563506A 2022-04-29 2023-04-28 上部顔面の皺線の処置 Pending JP2025514278A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2206362.2A GB202206362D0 (en) 2022-04-29 2022-04-29 Treatment of upper facial lines
GB2206362.2 2022-04-29
PCT/GB2023/051152 WO2023209403A1 (en) 2022-04-29 2023-04-28 Treatment of upper facial lines

Publications (2)

Publication Number Publication Date
JP2025514278A true JP2025514278A (ja) 2025-05-02
JP2025514278A5 JP2025514278A5 (enExample) 2026-05-08

Family

ID=81943827

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024563506A Pending JP2025514278A (ja) 2022-04-29 2023-04-28 上部顔面の皺線の処置

Country Status (9)

Country Link
US (1) US20250177278A1 (enExample)
EP (1) EP4514314A1 (enExample)
JP (1) JP2025514278A (enExample)
KR (1) KR20250005398A (enExample)
CN (1) CN119095579A (enExample)
AU (1) AU2023259716A1 (enExample)
CA (1) CA3245916A1 (enExample)
GB (1) GB202206362D0 (enExample)
WO (1) WO2023209403A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025093845A1 (en) * 2023-11-01 2025-05-08 Ipsen Biopharm Limited Use of high dose chimeric botulinum toxin a for the treatment of upper facial lines

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
IL99552A0 (en) 1990-09-28 1992-08-18 Ixsys Inc Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
DE102004043009A1 (de) 2004-09-06 2006-03-23 Toxogen Gmbh Transportprotein zum Einbringen chemischer Verbindungen in Nervenzellen
DE102005019302A1 (de) 2005-04-26 2006-11-16 Toxogen Gmbh Carrier zum Targeting von Nervenzellen
DK2154151T3 (da) 2005-09-19 2011-09-05 Allergan Inc Clostridiumtoksinaktiverbare clostridiumtoksiner
WO2010120766A1 (en) 2009-04-14 2010-10-21 Mcw Research Foundation, Inc. Engineered botulinum neurotoxin
US8853360B2 (en) 2010-06-23 2014-10-07 Wisconsin Alumni Research Foundation Engineered botulinum neurotoxin C1 with selective substrate specificity
EP2524963B1 (en) 2011-05-19 2018-10-31 Ipsen Bioinnovation Limited Methods for the manufacture of proteolytically processed polypeptides
MX359480B (es) 2012-05-30 2018-09-28 President And Fellows Of Harvard College Star Neurotoxina botulínica diseñada.
JP6156954B2 (ja) 2012-11-21 2017-07-05 イプセン バイオイノベーション リミテッド タンパク分解性にプロセシングされたポリペプチドの製造方法
RU2746736C2 (ru) 2015-03-26 2021-04-20 Президент Энд Феллоуз Оф Гарвард Колледж Сконструированный ботулинический нейротоксин
GB201607901D0 (en) 2016-05-05 2016-06-22 Ipsen Biopharm Ltd Chimeric neurotoxins
EP3481852B1 (en) 2016-07-08 2022-12-07 Children's Medical Center Corporation A novel botulinum neurotoxin and its derivatives
CA3057302A1 (en) * 2017-03-22 2018-09-27 Bonti, Inc. Botulinum neurotoxin serotype e for use in cosmetic treatment
GB202003813D0 (en) * 2020-03-16 2020-04-29 Ipsen Biopharm Ltd Treatment of upper facial lines

Also Published As

Publication number Publication date
US20250177278A1 (en) 2025-06-05
AU2023259716A1 (en) 2024-10-10
GB202206362D0 (en) 2022-06-15
KR20250005398A (ko) 2025-01-09
WO2023209403A1 (en) 2023-11-02
CN119095579A (zh) 2024-12-06
CA3245916A1 (en) 2023-11-02
EP4514314A1 (en) 2025-03-05

Similar Documents

Publication Publication Date Title
EP4401759B1 (en) Modified bont/a for use in the treatment of cervical dystonia
KR20220154739A (ko) 상부 얼굴 주름의 치료
US20250179461A1 (en) Modified Bont/A for Use in the Treatment of a Disorder Affecting an Eyelid Muscle of a Subject
AU2020357905C1 (en) Non-toxic clostridial neurotoxin polypeptides for use in treating neurological disorders
US20250177278A1 (en) Treatment of upper facial lines
US20250302928A1 (en) Treatment of cervical dystonia
US20250213662A1 (en) Bont/a for use in treating a facial dystonia
WO2025093845A1 (en) Use of high dose chimeric botulinum toxin a for the treatment of upper facial lines
JP2025514277A (ja) 四肢痙縮の処置
HK40118896A (en) Treatment of upper facial lines
WO2025093844A1 (en) Use of chimeric botulinum toxin a for treating blepharospasm and hemifacial spasm
HK40114696A (en) Treatment of cervical dystonia
HK40113476A (en) Treatment of limb spasticity

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260424

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260424